ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model

Eva Hurt-Camejo1

  • 1Translational Science & Experimental Medicine Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 83 Sweden; Division of Vascular Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, BioClinicum, 171 64 Solna, Sweden.

Journal of Lipid Research
|January 26, 2020
PubMed
Abstract

No abstract available in PubMed .